Arca
Skip to content
Tools
Tools

ADORA3: Adenosine receptor A3

G protein-coupled receptor (GPCR) for adenosine that plays significant roles in various physiological processes including immune regulation, cardioprotection and neuroprotection.

  • Drugs that act on it: 3
  • Approved: 0
  • In phases 1 to 3: 3
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on ADORA3, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 2
  • Other 1

Approved0

    Phase 32

    • Namodenoson
    • Piclidenoson

    Phase 20

      Phase 11

      • QAF805

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      NamodenosonPhase 3Can-Fite BioPharmaSmall moleculeAgonistAdenosine A3 receptor agonist2
      PiclidenosonPhase 3Can-Fite BioPharmaSmall moleculeAgonistAdenosine A3 receptor agonist2
      QAF805Phase 1—OtherAntagonistAdenosine A3 receptor antagonist0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 4 in all, from ClinicalTrials.gov.
      An Open-label, Phase 2 Pilot Study on the Efficacy and Safety of Piclidenoson in Patients With Lowe SyndromePiclidenosonPhase 2Not yet recruitingCan-Fite BioPharmaFeb 13, 2026
      A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and EfficacyPiclidenosonPhase 3Not yet recruitingCan-Fite BioPharmaOct 16, 2024
      Namodenoson Treatment of Advanced Pancreatic CancerNamodenosonPhase 2RecruitingCan-Fite BioPharmaApr 29, 2024
      Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 CirrhosisNamodenosonPhase 3RecruitingCan-Fite BioPharmaJan 21, 2022

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      • Paroxysmal tachycardia0.59
      • Apnea0.57
      • Wolff-Parkinson-White syndrome0.56
      • Pain0.56
      • Airway obstruction0.55
      • Cardiovascular disorder0.37

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL256, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P0DMS8, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.